VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER
Vistakon, Division of Johnson & Johnson Vision Car · Decision date Dec 16, 2025
What did the FDA decide?
FDA records P040045/S141 as a supplement to PMA P040045, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 16, 2025.
FDA approval order statement
an update to the control plan for material characteristics for the Vistakon (senofilcon A) and (etafilcon A) Brand Contact Lenses
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Dec 16, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P040045/S141
- Regulatory pathway
- PMA supplement
- Product code
- LPM
- Decision code
- OK30
- Decision date
- Dec 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Product code
- LPM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P040045. Subsequent supplements may change the device or its indications.
FDA decision timeline
P040045 · Original PMA
VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER
P040045/S141 received
Application receipt date recorded by FDA.
P040045/S141 · FDA decision
30-Day Notice
P040045/S142 · Related supplement
VISTAKON (senofilcon A) Brand Contact Lenses
P040045/S143 · Related supplement
VISTAKON (senofilcon A) Contact Lenses
P040045/S144 · Related supplement
VISTAKON (senofilcon A) contact lenses
P040045/S145 · Related supplement
VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER
P040045/S146 · Related supplement
VISTAKON (SENOFILCON A) Brand Contact Lenses
P040045/S147 · Related supplement
VISTAKON (senofilcon A) Brand Contact Lenses
Timeline entries are records held by MedtechLedger for P040045. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040045
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Vistakon, Division of Johnson & Johnson Vision Car | PMA approval | Dec 20, 2005 | FDA | |
VISTAKON (senofilcon A) Brand Contact LensesP040045/S142 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Apr 17, 2026 | FDA |
VISTAKON (senofilcon A) Contact LensesP040045/S143 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Apr 29, 2026 | FDA |
VISTAKON (senofilcon A) contact lensesP040045/S144 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | May 4, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
| CooperVision, Inc. | PMA supplement | Jul 7, 2026 | FDA | |
| CooperVision, Inc. | PMA supplement | Jun 16, 2026 | FDA | |
| Alcon Laboratories, Inc. | PMA supplement | May 29, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vistakon, Division of Johnson & Johnson Vision Car
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7500 Centurion Pkwy., Suite 100 - Erca, Jacksonville, FL, 32256
Sources and methodology
- Original FDA record: P040045/S141
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





